170 related articles for article (PubMed ID: 11145435)
1. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Osterborg A; Henriksson L; Mellstedt H
Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
[TBL] [Abstract][Full Text] [Related]
2. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.
Mellstedt H; Osterborg A
Pathol Biol (Paris); 1999 Feb; 47(2):211-5. PubMed ID: 10192891
[TBL] [Abstract][Full Text] [Related]
3. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
5. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.
Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
Br J Haematol; 1996 Mar; 92(4):840-6. PubMed ID: 8616076
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
7. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
[TBL] [Abstract][Full Text] [Related]
8. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
Osterborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Blood; 1998 Apr; 91(7):2459-66. PubMed ID: 9516146
[TBL] [Abstract][Full Text] [Related]
9. Deletion of idiotype (Id)-specific T cells in multiple myeloma.
Bogen B; Schenck K; Munthe LA; Dembic Z
Acta Oncol; 2000; 39(7):783-8. PubMed ID: 11145433
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
[TBL] [Abstract][Full Text] [Related]
11. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.
Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Osterborg A; Mellstedt H
Int J Cancer; 1999 Mar; 80(5):671-80. PubMed ID: 10048965
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
[TBL] [Abstract][Full Text] [Related]
13. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
15. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
Hong S; Qian J; Li H; Yang J; Lu Y; Zheng Y; Yi Q
Cancer Immunol Immunother; 2012 Apr; 61(4):561-71. PubMed ID: 22002243
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model.
Stritzke J; Zunkel T; Steinmann J; Schmitz N; Uharek L; Zeis M
Br J Haematol; 2003 Jan; 120(1):27-35. PubMed ID: 12492573
[TBL] [Abstract][Full Text] [Related]
17. Identification of human idiotype-specific T cells in lymphoma and myeloma.
Weng J; Neelapu SS; Woo AF; Kwak LW
Curr Top Microbiol Immunol; 2011; 344():193-210. PubMed ID: 20549471
[TBL] [Abstract][Full Text] [Related]
18. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).
Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Ann Oncol; 2008 Jun; 19(6):1172-9. PubMed ID: 18272909
[TBL] [Abstract][Full Text] [Related]
19. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
20. Idiotype vaccination of myeloma patients after chemotherapy.
Massaia M
Acta Oncol; 2000; 39(7):807-8. PubMed ID: 11145437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
